Stocks Overview

LAST PRICE
27.2900
TODAY'S CHANGE (%)
0.0000 (0.0000%)

Bid / Lots
25.3300/ 3
Ask / Lots
34.2800/ 1
Open / Previous Close
0.0000 / 27.2900
Day Range
---
52 Week Range
Low 18.1615
High 45.5800
Volume
4
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TSX Comp
TSX Venture
DJIA
S&P 500
NASDAQ

Price Comparison Graph. See accessible table below

1 Day Comparison Chart Accessibility Table. Monday's close: 27.37
Time	Volume	IMVT
09:32 ET	8344	27
09:34 ET	2814	27.14
09:36 ET	2789	27.22
09:38 ET	600	27.13
09:39 ET	2503	27.08
09:41 ET	830	27.32
09:43 ET	200	27.26
09:45 ET	2300	27.28
09:48 ET	600	27.23
09:52 ET	600	27.09
09:54 ET	2764	27.285
09:56 ET	857	27.245
09:57 ET	1026	27.19
09:59 ET	15463	27.24
10:01 ET	100	27.275
10:03 ET	200	27.23
10:06 ET	1314	27.48
10:08 ET	409	27.44
10:10 ET	4983	27.425
10:12 ET	300	27.47
10:15 ET	1765	27.48
10:17 ET	3696	27.3
10:19 ET	100	27.315
10:21 ET	1620	27.35
10:24 ET	200	27.38
10:26 ET	100	27.35
10:28 ET	100	27.32
10:30 ET	800	27.33
10:32 ET	500	27.35
10:33 ET	629	27.34
10:35 ET	100	27.36
10:37 ET	400	27.33
10:39 ET	1018	27.29
10:42 ET	400	27.3
10:44 ET	1317	27.355
10:46 ET	600	27.38
10:48 ET	800	27.35
10:51 ET	1263	27.36
10:53 ET	1400	27.31
10:57 ET	300	27.33
11:00 ET	400	27.315
11:04 ET	1400	27.43
11:06 ET	4538	27.35
11:08 ET	1180	27.35
11:09 ET	694	27.4788
11:11 ET	531	27.49
11:13 ET	3456	27.4125
11:15 ET	400	27.39
11:18 ET	100	27.39
11:20 ET	6825	27.24
11:22 ET	204	27.29
11:24 ET	789	27.23
11:26 ET	1173	27.27
11:27 ET	100	27.255
11:29 ET	2883	27.25
11:31 ET	400	27.255
11:33 ET	3300	27.26
11:36 ET	1190	27.29
11:38 ET	347	27.275
11:42 ET	100	27.28
11:44 ET	3907	27.19
11:45 ET	605	27.25
11:47 ET	100	27.27
11:49 ET	300	27.27
11:51 ET	643	27.21
11:54 ET	400	27.25
11:56 ET	626	27.28
11:58 ET	1050	27.34
12:00 ET	1900	27.32
12:02 ET	300	27.305
12:03 ET	200	27.34
12:05 ET	600	27.29
12:07 ET	100	27.33
12:09 ET	2001	27.35
12:12 ET	500	27.37
12:14 ET	500	27.4
12:16 ET	1289	27.35
12:18 ET	100	27.37
12:20 ET	2200	27.35
12:21 ET	3719	27.355
12:23 ET	700	27.35
12:25 ET	1200	27.335
12:27 ET	900	27.37
12:30 ET	625	27.48
12:32 ET	1003	27.47
12:34 ET	1779	27.4
12:36 ET	8724	27.4
12:38 ET	2919	27.385
12:39 ET	600	27.35
12:41 ET	1009	27.32
12:43 ET	400	27.34
12:45 ET	1200	27.39
12:48 ET	503	27.39
12:50 ET	1854	27.51
12:52 ET	1800	27.52
12:54 ET	100	27.53
12:56 ET	250	27.492
12:57 ET	3879	27.4
12:59 ET	926	27.39
01:01 ET	100	27.35
01:03 ET	1700	27.36
01:06 ET	2850	27.36
01:08 ET	200	27.34
01:12 ET	1750	27.35
01:14 ET	300	27.35
01:15 ET	100	27.345
01:17 ET	200	27.37
01:19 ET	100	27.32
01:21 ET	5358	27.34
01:24 ET	100	27.36
01:26 ET	500	27.375
01:28 ET	4139	27.375
01:30 ET	1919	27.38
01:32 ET	3430	27.35
01:33 ET	200	27.34
01:35 ET	3110	27.37
01:39 ET	2500	27.35
01:42 ET	2220	27.3
01:44 ET	900	27.31
01:46 ET	300	27.3
01:48 ET	200	27.3
01:50 ET	300	27.3
01:51 ET	930	27.32
01:53 ET	2281	27.34
01:55 ET	400	27.36
01:57 ET	1799	27.34
02:00 ET	1474	27.32
02:02 ET	100	27.325
02:04 ET	200	27.33
02:06 ET	4702	27.31
02:08 ET	715	27.3
02:09 ET	1146	27.3
02:11 ET	758	27.33
02:15 ET	300	27.36
02:18 ET	603	27.39
02:20 ET	2000	27.34
02:22 ET	5280	27.3
02:24 ET	1630	27.3
02:26 ET	3800	27.14
02:27 ET	3400	27.18
02:29 ET	3902	27.275
02:31 ET	677	27.29
02:33 ET	200	27.3
02:38 ET	1177	27.255
02:40 ET	2746	27.29
02:42 ET	3816	27.27
02:44 ET	1220	27.26
02:45 ET	100	27.255
02:47 ET	3127	27.26
02:49 ET	1321	27.24
02:51 ET	4815	27.16
02:54 ET	1292	27.21
02:56 ET	2432	27.21
02:58 ET	955	27.23
03:00 ET	2267	27.185
03:02 ET	3138	27.2
03:03 ET	3005	27.14
03:05 ET	1802	27.13
03:07 ET	1651	27.16
03:09 ET	6424	27.22
03:12 ET	969	27.14
03:14 ET	1309	27.08
03:16 ET	1401	27.08
03:18 ET	240	27.095
03:20 ET	7743	27.17
03:21 ET	7202	27.21
03:23 ET	2453	27.21
03:25 ET	3071	27.24
03:27 ET	1043	27.21
03:30 ET	1800	27.21
03:32 ET	2501	27.22
03:34 ET	5250	27.24
03:36 ET	940	27.23
03:38 ET	348	27.22
03:39 ET	3550	27.25
03:41 ET	4268	27.24
03:43 ET	1500	27.24
03:45 ET	4785	27.23
03:48 ET	5621	27.24
03:50 ET	4468	27.24
03:52 ET	7773	27.205
03:54 ET	8841	27.205
03:56 ET	7826	27.23
03:57 ET	10431	27.28
03:59 ET	28634	27.29

Data delayed at least 15 minutes.

Jun 3, 2024
- DJ Immunovant Is Maintained at Outperform by Oppenheimer, from 8:37AM ET on Monday Jun 03, 2024 by Dow Jones
  8:37AM ET on Monday Jun 03, 2024 by Dow Jones
May 30, 2024
- DJ Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co., from 7:35AM ET on Thursday May 30, 2024 by Dow Jones
  7:35AM ET on Thursday May 30, 2024 by Dow Jones
May 29, 2024
- Press Release: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, from 4:01PM ET on Wednesday May 29, 2024 by Dow Jones
  4:01PM ET on Wednesday May 29, 2024 by Dow Jones
- Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, from 4:01PM ET on Wednesday May 29, 2024 by Dow Jones
  4:01PM ET on Wednesday May 29, 2024 by Dow Jones

0 New Today

Industry Peers Overview Table
Company sortable	Market Cap sortable	P/E Ratio (TTM) sortable	EPS Growth (5yr) sortable
United StatesIMVT Immunovant Inc	4.0B	-14.5x	---
United StatesRNA Avidity Biosciences Inc	4.1B	-13.2x	---
United StatesBBIO BridgeBio Pharma Inc	4.4B	-7.2x	---
United StatesMRUS Merus NV	3.8B	-20.8x	---
United StatesCRNX Crinetics Pharmaceuticals Inc	3.5B	-11.9x	---
United StatesDYN Dyne Therapeutics Inc	3.4B	-8.6x	---
As of 2024-06-26

Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

Contact Information

Headquarters: 320 West 37Th StreetNEW YORK, NY, United States 10018
Phone: 917-580-3099
Fax: 302-636-5454

Executives

Executive Chairman of the Board: Frank Torti
Chief Executive Officer of IMVT Corporation, Director: Peter Salzmann
Chief Financial Officer: Eva Barnett
Chief Technology Officer: Jay Stout
Chief Development Officer: Julia Butchko

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Skip section

INK Company InsiderDetailed daily analysis of insider activity and holdings for stocks and income trusts listed in Canada, based on filings from SEDI®.

Fundamentals Table
Market Cap	$4.0B
Revenue (TTM)	$0.00
Shares Outstanding	146.1M
Dividend Yield	0.00%
Annual Dividend Rate	---
Ex-Dividend Date	01-01-01
Pay Date	01-01-01
Beta	0.72
EPS	$-1.89
Book Value	$4.24
P/E Ratio	-14.5x
Price/Sales (TTM)	---
Price/Cash Flow (TTM)	---
Operating Margin	---

*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.

Immunovant Inc
NASDAQ:IMVTUnited States

Search Criteria

Charts

Recent News

Jun 3, 2024

DJ Immunovant Is Maintained at Outperform by Oppenheimer, from 8:37AM ET on Monday Jun 03, 2024 by Dow Jones

May 30, 2024

DJ Immunovant Price Target Maintained With a $51.00/Share by HC Wainwright & Co., from 7:35AM ET on Thursday May 30, 2024 by Dow Jones

May 29, 2024

Press Release: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, from 4:01PM ET on Wednesday May 29, 2024 by Dow Jones

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, from 4:01PM ET on Wednesday May 29, 2024 by Dow Jones

Biotechnology Industry Peers

Company Information

Contact Information

Executives

Ratings

Reports

Fundamentals

Calendar